Takeda launches ORZEYFUL in Japan and China as first-in-class orexin agonist for narcolepsy type 1

Takeda launched ORZEYFUL in Japan and China as a first-in-class orexin agonist for narcolepsy type 1, with a US launch set for next month after DEA scheduling.

Detected & updated continuously · Source: Nebula